作者
Danijela Gnjidic, SN Hilmer, FM Blyth, Vasin Naganathan, RG Cumming, DJ Handelsman, AJ McLachlan, DR Abernethy, Emily Banks, DG Le Couteur
发表日期
2012/3
期刊
Clinical Pharmacology & Therapeutics
卷号
91
期号
3
页码范围
521-528
简介
Evidence about the association between treatment with high–risk medicines and frailty in older individuals is limited. We investigated the relationship between high–risk prescribing and frailty at baseline, as well as 2–year incident frailty, in 1,662 men ≥70 years of age. High–risk prescribing was defined as polypharmacy (≥5 medicines), hyperpolypharmacy (≥10 medicines), and by the Drug Burden Index (DBI), a dose–normalized measure of anticholinergic and sedative medicines. At baseline, frail participants had adjusted odds ratios (ORs) of 2.55 (95% confidence interval, CI: 1.69–3.84) for polypharmacy, 5.80 (95% CI: 2.90–11.61) for hyperpolypharmacy, and 2.33 (95% CI: 1.58–3.45) for DBI exposure, as compared with robust participants. Of the 1,242 men who were robust at baseline, 6.2% developed frailty over two years. Adjusted ORs of incident frailty were 2.45 (95% CI: 1.42–4.23) for polypharmacy, 2.50 …
学术搜索中的文章
D Gnjidic, SN Hilmer, FM Blyth, V Naganathan… - Clinical Pharmacology & Therapeutics, 2012